New-onset graves’ disease after the initiation of nivolumab therapy for gastric cancer: a case report

BMC Endocrine Disorders

Table 1 TSH, FT3, FT4, and Tg levels and TRAb and TSAb titres in our patient

	Day of nivolumab administration
	0	21	43	72	100	107	114	121	139
TSH (μIU/mL)	2.822	0.133	< 0.010	< 0.010	< 0.010	< 0.010	0.027	0.034	0.010
FT3 (pg/mL)	1.73	2.82	15.30	2.57	1.80	< 1.50	1.98	1.58	1.67
FT4 (ng/dL)	0.86	1.15	> 5.00	1.18	0.82	0.80	0.70	0.70	1.18
TRAb (IU/L)	< 1.0	3.1	24.2	27.5	NA	NA	NA	NA	10.7
TSAb (%)	95	227	2184	NA	NA	1683	NA	NA	667
Tg (ng/mL)	11.20	40.70	347.00						28.70

Day 0: first administration of nivolumab, Day 21: second administration of nivolumab
The normal range of the thyroid parameters is as follows: TSH (0.350–4.940 μIU/mL), FT3 (1.88–3.18 pg/mL), FT4 (0.70–1.48 ng/dL), TRAb (< 1.0 IU/L), TSAb (≤ 120%), and Tg (≤ 33.70 ng/mL)

ISSN: 1472-6823